Versiti Acquires Cenetron Central Laboratories and Salus IRB
Versiti, has announced the acquisition of Texas-based Cenetron Central Laboratories, and its subsidiary, Salus IRB, offering both organizations the opportunity to expand clinical trial services and expertise.
“By joining forces with an industry leader such as Cenetron, we gain the strength of an organization that specializes in pre-analytical activities that are critical to the success of clinical trials,” said Versiti President and CEO Chris Miskel. “Clinical trials are critical to medical advances that translate to patient care.”
Cenetron will provide Versiti’s diagnostic laboratories with a spectrum of clinical trial solutions from project initiation, kit development and sample logistics, specialized testing, data management, and project management.
The acquisition will not impact Cenetron’s 40 employees, and the laboratory will maintain its name and current location in Austin. Versiti, headquartered in Milwaukee, has 2,000 employees at its locations in Illinois, Indiana, Michigan, Ohio and Wisconsin.
“Versiti and Cenetron are dedicated to a common mission of advancing medical science, and patient care, through clinical trials,” said Cenetron President Dwight DuBois, M.D. “The entire Cenetron organization is both excited and proud to be aligned with an organization with Versiti's sterling reputation."
Dr. DuBois will remain at Cenetron as the laboratory’s medical director.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
